依据传染病防控基本原则，精准预防新型冠状病毒感染

毛青

doi:10.16016/j.1000-5404.202112023

您当前的位置：

首页 >

文章列表页 >

依据传染病防控基本原则，精准预防新型冠状病毒感染

公共卫生与预防医学 | 更新时间：2026-01-09

- 依据传染病防控基本原则，精准预防新型冠状病毒感染
- Accurately prevent SARS-CoV-2 infections based on the basic principles of infectious disease prevention and control
- 陆军军医大学学报 2022年44卷第1期页码：28-33
- 作者机构：
  
  400038 重庆，陆军军医大学（第三军医大学）第一附属医院感染病科，全军感染病研究所
- 作者简介：
  
  [毛青，博士，教授，主任医师，博士研究生导师，长江学者特聘教授。任中华医学会医学病毒学分会副主任委员、中华医学会感染病学分会常务委员、中国医师协会感染科医师分会常务委员、解放军传染病专委会副主任委员和生物军控与履约专业委员会委员、重庆市医学会感染病学分会主任委员，入选重庆市学术技术带头人和重庆英才名师名家。担任Gastroenterology和Clinical Gastroenterology and Hepatology审稿人、《中华实验和临床病毒学杂志》副主编及多家杂志编委。作为首席专家先后参与抗击非典、埃博拉（非洲）和新冠（武汉）疫情及“国际军事比赛-2021”等重大非战争军事行动。先后主持了973计划课题、国家科技重大专项课题、国家科技支撑计划、国家自然科学基金及军队和重庆市科研课题10余项。参与获得国家科技进步二等奖1项、军队科技进步二等奖2项、重庆市科技进步二等奖1项。在国内期刊上发表论文100余篇，在SCI收录的国外期刊发表论文30余篇，主编专著6部。主要从事病毒性肝炎和新发传染病防治方面的研究。E-mail：qingmao@tmmu.edu.cn MAO Qing, qingmao@tmmu.edu.cn
- 基金信息：
- DOI：10.16016/j.1000-5404.202112023
  中图分类号： R183;R512.99
- 收稿：2021-12-03，
  
  修回：2021-12-14，
  
  纸质出版：2022-01-15
- 稿件说明：
移动端阅览
毛青. 依据传染病防控基本原则，精准预防新型冠状病毒感染[J]. 陆军军医大学学报, 2022,44(1):28-33.

Qing MAO. Accurately prevent SARS-CoV-2 infections based on the basic principles of infectious disease prevention and control[J]. Journal of Army Medical University, 2022, 44(1): 28-33.
毛青. 依据传染病防控基本原则，精准预防新型冠状病毒感染[J]. 陆军军医大学学报, 2022,44(1):28-33. DOI： 10.16016/j.1000-5404.202112023.

Qing MAO. Accurately prevent SARS-CoV-2 infections based on the basic principles of infectious disease prevention and control[J]. Journal of Army Medical University, 2022, 44(1): 28-33. DOI： 10.16016/j.1000-5404.202112023.

摘要

新型冠状病毒肺炎（简称新冠肺炎，coronavirus disease 2019，COVID-19）疫情暴发流行已两年，持续在全世界肆虐。由于各国采取的防控政策和措施不同，疫苗分配不均，加之新型冠状病毒（severe acute respiratory syndrome coronavirus 2

SARS-CoV-2）变异迅速，导致疫情仍十分严重。随着疫情的发展，对新冠肺炎的临床特征、流行病学及SARS-CoV-2的生物学特征等有了深入研究和认识。人群普遍接种疫苗在控制新冠肺炎疫情中起到决定性作用，但注射疫苗后仍然存在一定比例的突破性感染。因此，依据传染病防控基本原则（管理传染源、切断传播途径、保护易感人群）进行物理防护仍十分重要。实践证明，“普遍疫苗接种+有效物理防护”是全面控制新冠肺炎疫情的根本措施，两者不可或缺。

Abstract

The novel coronavirus pneumonia (coronavirus disease 2019

COVID-19) pandemic has been raging around the world for almost 2 years. Due to the different prevention and control policies and measures adopted by various countries

uneven distribution of vaccines and rapid mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

the pandemic is still very serious. With the process of the pandemic

in-depth research and understanding of the clinical characteristics and epidemiology of COVID-19 and biological characteristics of SARS-CoV-2 have been made. Widespread vaccination of the population plays a decisive role in the control of the COVID-19 pandemic. However

there is still a certain percentage of breakthrough infections after vaccination. Therefore

the physical protection is still very important based on the basic principles of infectious disease prevention and control (management of the source of infection

cutting off the route of transmission and protection of the susceptible population). Practice has proved that "widespread vaccination + effective physical precautions" is a fundamental measure for comprehensive control of COVID-19 pandemic

and both are indispensable.

关键词

Keywords

references

WHO Coronavirus (COVID-19) Dashboard[R/OL]. [2021-12-01]. https://covid19.who.int/.

COVID-19 advice for the public: Getting vaccinated[EB/OL]. (2021-11-15)[2021-12-08]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.

CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1-April 30, 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(21): 792-793. DOI: 10.15585/mmwr.mm7021e3.

ROVIDA F, CASSANITI I, PAOLUCCI S, et al . SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers[J ] . Nat Commun, 2021, 12(1): 6032. DOI: 10.1038/s41467-021-26154-6.

CEVIK M, TATE M, LLOYD O, et al . SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis[J ] . Lancet Microbe, 2021, 2(1): e13-e22. DOI: 10.1016/S2666-5247(20)30172-5.

CEVIK M, KUPPALLI K, KINDRACHUK J, et al . Virology, transmission, and pathogenesis of SARS-CoV-2[J ] . BMJ, 2020: m3862. DOI: 10.1136/bmj.m3862.

ZHENG S F, FAN J, YU F, et al . Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, January-March 2020: retrospective cohort study[J ] . BMJ, 2020: m1443. DOI: 10.1136/bmj.m1443.

MEYEROWITZ E A, RICHTERMAN A, BOGOCH I I, et al . Toward s an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2[J ] . Lancet Infect Dis, 2021, 21(6): e163-e169. DOI: 10.1016/s1473-3099(20)30837-9.

BUITRAGO-GARCIA D, EGLI-GANY D, COUNOTTE M J, et al . Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis[J ] . PLoS Med, 2020, 17(9): e1003346. DOI: 10.1371/journal.pmed.1003346.

LAVEZZO E, FRANCHIN E, CIAVARELLA C, et al . Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'[J ] . Nature, 2020, 584(7821): 425-429. DOI: 10.1038/s41586-020-2488-1.

国家卫生健康委宣传司. 国务院联防联控机制2021年11月6日新闻发布会文字实录[EB/OL]. (2021-11-06)[2021-12-08]. http://www.nhc.gov.cn/xcs/fkdt/202111/28aeb8577b8747ed877f582d50f51035.shtml.

Publicity Department of National Health Commission. Transcript of the press conference of the joint prevention and control mechanism of the State Council on November 6, 2021[EB/OL]. (2021-11-06)[2021-12-08]. http://www.nhc.gov.cn/xcs/fkdt/202111/28aeb8577b8747ed877f582d50f51035.shtml.

金振娅. 对返校学生"适时抽检"——教育部向全国推广福建防疫"实招"[N/OL]. 光明日报, 2021-09-17[2021-12-08]. http://www.moe.gov.cn/jyb_xwfb/s5147/202109/t20210917_564006.html.

JIN Z Y. "Sampling inspections at the right time" for returning students—the Ministry of Education promotes Fujian's "practical measures" for epidemic prevention throughout the country[N/OL]. Guangming Daily, 2021-09-17[2021-12-08]. http://www.moe.gov.cn/jyb_xwfb/s5147/202109/t20210917_564006.html.

国务院应对新型冠状病毒肺炎疫情联防联控机制综合组. 新型冠状病毒肺炎防控方案(第八版)[R/OL]. (2021-05-14)[2021-12-08]. http://www.nhc.gov.cn/xcs/zhengcwj/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml.

The Joint Prevention and Control Group of the State Council Against New Coronavirus Pneumonia. New coronavirus pneumonia prevention and control plan (8th Edition)[R/OL]. (2021-05-14)[2021-12-08]. http://www.nhc.gov.cn/xcs/zhengcwj/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml.

国家卫生健康委办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第八版修订版)[R/OL]. (2021-04-15)[2021-12-08]. http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b.shtml.

General Office of National Health Commission, Office of the State Administration of Traditional Chinese Medicine.New coronavirus pneumonia diagnosis and treatment plan (Trial 8th Edition, Revised)[R/OL]. (2021-04-15)[2021-12-08]. http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b.shtml.

MORAWSKA L, CAO J. Airborne transmission of SARS-CoV-2: The world should face the reality[J]. Environ Int, 2020, 139: 105730. DOI: 10.1016/j.envint.2020.105730.

LEE B U. Why does the SARS-CoV-2 delta VOC spread so rapidly? Universal conditions for the rapid spread of respiratory viruses, minimum viral loads for viral aerosol generation, effects of vaccination on viral aerosol generation, and viral aerosol clouds[J]. Int J Environ Res Public Heal, 2021, 18(18): 9804. DOI: 10.3390/ijerph18189804.

HAMMING I, TIMENS W, BULTHUIS M L, et al . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J ] . J Pathol, 2004, 203(2): 631-637. DOI: 10.1002/path.1570.

HIKMET F, MÉAR L, EDVINSSON Å, et al . The protein expression profile of ACE2 in human tissues[J ] . Mol Syst Biol, 2020, 16(7): e9610. DOI: 10.15252/msb.20209610.

KYROU I, RANDEVA H S, SPANDIDOS D A, et al . Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19[J ] . Signal Transduct Target Ther, 2021, 6(1): 1-3. DOI: 10.1038/s41392-020-00460-9.

DAVIES J, RANDEVA H S, CHATHA K, et al . Neuropilin-1 as a new potential SARS-CoV-2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID-19[J ] . Mol Med Rep, 2020, 22(5): 4221-4226. DOI: 10.3892/mmr.2020.11510.

XIE X, LI Y, CHWANG A T, et al . How far droplets can move in indoor environments: revisiting the Wells evaporation-falling curve[J ] . Indoor Air, 2007, 17(3): 211-225. DOI: 10.1111/j.1600-0668.2007.00469.x.

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020[J]. China CDC Wkly, 2020, 2(8): 113-122.

STOKES E K, ZAMBRANO L D, ANDERSON K N, et al . Coronavirus disease 2019 case surveillance—United States, January 22-may 30, 2020[J ] . MMWR Morb Mortal Wkly Rep, 2020, 69(24): 759-765. DOI: 10.15585/mmwr.mm6924e2.

KHAN M I, BAIG M H, MONDAL T, et al . Impact of the double mutants on spike protein of SARS-CoV-2 B. 1.617 lineage on the human ACE2 receptor binding: a structural insight[J ] . Viruses, 2021, 13(11): 2295. DOI: 10.3390/v13112295.

Scientific Advisory Group for Emergencies. Imperial College London: Delta (B. 1.617.2) transmission in England-risk factors and transmission advantage, 1 June 2021[R/OL]. (2021-06-14)[2021-12-08]. https://www.gov.uk/government/publications/imperial-college-london-delta-b16172-transmission-in-england-risk-factors-and-transmission-advantage-1-june-2021.

POLACK F P, THOMAS S J, KITCHIN N, et al . Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine[J ] . N Engl J Med, 2020, 383(27): 2603-2615. DOI: 10.1056/nejmoa2034577.

BADEN L R, SAHLY H M EL, ESSINK B, et al . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J ] . N Engl J Med, 2021, 384(5): 403-416. DOI: 10.1056/NEJMoa2035389.

XIA S L, ZHANG Y T, WANG Y X, et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial[J ] . Lancet Infect Dis, 2021, 21(1): 39-51. DOI: 10.1016/S1473-3099(20)30831-8.

ZHANG Y J, ZENG G, PAN H X, et al . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical tria l[J ] . Lancet Infect Dis, 2021, 21(2): 181-192. DOI: 10.1016/S1473-3099(20)30843-4.

LOPEZ BERNAL J, ANDREWS N, GOWER C, et al . Effectiveness of covid-19 vaccines against the B. 1.617.2 (delta) variant[J ] . N Engl J Med, 2021, 385(7): 585-594. DOI: 10.1056/nejmoa2108891.

TANG P, HASAN M R, CHEMAITELLY H, et al . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar[J ] . Nat Med, 2021: 1-8. DOI: 10.1038/s41591-021-01583-4.

CALLAWAY E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature, 2021, 600(7887): 21. DOI: 10.1038/d41586-021-03552-w.

MIZRAHI B, LOTAN R, KALKSTEIN N, et al . Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine[J ] . Nat Commun, 2021, 12(1): 6379. DOI: 10.1038/s41467-021-26672-3.

KESKIN A U, BOLUKCU S, CIRAGIL P, et al . SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen[J ] . J Med Virol, 2022, 94(1): 39-41. DOI: 10.1002/jmv.27350.

WHO. With a fast-moving pandemic, no one is safe, unless everyone is safe[EB/OL]. [2021-12-08].https://www.who.int/initiatives/act-accelerator/covax.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

胃癌的科学预防、早期诊断与精准治疗

广泛耐药肺炎克雷伯菌感染的流行病学调查和危险因素分析

类鼻疽杆菌慢性感染BALB/c小鼠模型的建立

某部Ⅲ类人员长途行军期间足踝训练伤调查

开放楔形胫骨高位截骨术后感染的危险因素分析